 |
|
|
| |
High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV
Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials
|
| |
| |
Reported by Jules Levin
HEPDART 2015, December 6-10, 2015, Wailea, Hawaii
IM Jacobson1*, K Agarwal2, B Willems3, E Lawitz4, E Schiff5, M Bouliere6, E Svarovskaia7, B Doehle7, X Ding7, J McNally7, A Osinusi7, DM Brainard7, JG McHutchison7, N Reau8, A Mangia9, M Sulkowski10
1Mount Sinai Beth Israel Medical Center, New York, US; 2Institute of Liver Studies, Kings College Hopsital, London,UK; 3Centre Hospitalier de l Universite de Montreal, Universite de Montreal, Montreal, Canada; 4Texas Liver Institute, University of Texas Health Science Center, San Antonio, US;
5University of Miami, Miami, US; 6Hopital Saint Joseph, Marseilles, France; 7Gilead Sciences Inc., Foster City, US; 8University of Chicago Medical Center, Chicago, US; 9Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 10Johns Hopkins University, Baltimore
AASLD: Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)
|
| |
|
|
|
|
|
